Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (Alliance)
- Citation:
- Ann Oncol vol 27 (2) 339-344
- Year:
- 2016
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 5
- Parents:
- 955
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- U24CA196171, U10CA180821, U10CA180882, U10 CA180821, P30 CA015083, U10 CA180882, U24 CA196171, U10 CA25224, U10 CA180867
- Corr. Author:
- Authors:
- H. H. Yoon N. R. Foster J. P. Meyers P. D. Steen D. W. Visscher R. Pillai D. M. Prow C. M. Reynolds B. T. Marchello R. B. Mowat B. I. Mattar C. Erlichman M. P. Goetz
- Networks:
- IWORC, KS055, LAPS-MN026, MCRC, OH016, SANFORD
- Study
- NCCTG-N0871
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- cancer of unknown primary, tissue of origin, everolimus, platinum chemotherapy, taxane chemotherapy, expression profile